Purple Biotech (PPBT) Total Current Liabilities (2014 - 2026)

Purple Biotech (PPBT) has 13 years of Total Current Liabilities data on file, last reported at $4.6 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 66.53% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $4.6 million, a 66.53% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, up 94.46% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $4.6 million, down from $7.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for PPBT reached as high as $9.7 million in Q4 2023 and fell as low as $2.2 million in Q2 2025.
• Historically, Total Current Liabilities has averaged $5.9 million across 5 years, with a median of $5.9 million in 2022.
• On a YoY basis, Total Current Liabilities climbed as much as 94.46% in 2025 and fell as far as 67.59% in 2025.
• Year by year, Total Current Liabilities stood at $7.1 million in 2022, then jumped by 37.45% to $9.7 million in 2023, then plunged by 58.9% to $4.0 million in 2024, then jumped by 94.46% to $7.8 million in 2025, then plunged by 40.76% to $4.6 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $4.6 million in Q1 2026, $7.8 million in Q4 2025, and $6.1 million in Q3 2025.